Bachem Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCHMF research report →
About the company
Bachem Holding AG is a global partner to pharmaceutical and biotechnology companies, supplying crucial products and services for every stage from early-stage research and clinical trials to full-scale commercialization. The company specializes in the creation, manufacturing, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide chemical entities (NCEs). Beyond these, Bachem also offers established commercial NCEs and generic medications.
- CEO
- Anne-Kathrin Stoller
- IPO
- 2011
- Employees
- 2,207
- HQ
- Bubendorf, CH
Price Chart
- Market Cap
- $6.54B
- P/E
- 39.07
- P/S
- 8.36
- P/B
- 3.99
- EV/EBITDA
- 32.46
- Div Yield
- 1.16%
- Gross Margin
- 28.74%
- Op Margin
- 21.62%
- Net Margin
- 21.41%
- ROE
- 10.56%
- ROIC
- 8.12%
- Revenue
- $695.40M · 14.89%
- Net Income
- $148.86M · 23.80%
- EPS
- $1.98 · 23.75%
- Op Income
- $150.36M
- FCF YoY
- 65.13%
- 52W High
- $94.62
- 52W Low
- $60.51
- 50D MA
- $89.45
- 200D MA
- $73.59
- Beta
- 0.81
- Avg Volume
- 99
Get TickerSpark's AI analysis on BCHMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BCHMF coverage
Recent articles, reports, and earnings notes.
No research on BCHMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCHMF report →Similar companies
Peers in the same neighborhood.